Dr. Qin Yan
Associate Professor, Department of Pathology, Yale University
Hosted by Dr. Marc Meneghini
April 21st @ 4PM
1 King’s College Circle, Medical Sciences Building, Room 4171
Epigenetic aberrations often lead to cancer and other human diseases. The KDM5/JARID1 demethylases play critical roles in tumor formation, metastasis and drug resistance, and therefore are novel targets for cancer treatment. We have identified novel mechanisms by which the KDM5 enzymes regulate gene expression and promote tumorigenesis. Our drug development platform has identified not only pan-KDM5 inhibitors, but also inhibitors with selective specificity against the KDM5 family members. The implications of these results in cancer treatment will be discussed.